199 related articles for article (PubMed ID: 32763659)
1. Oral cinacalcet responsiveness in non-parathyroid hormone mediated hypercalcemia of malignancy.
Sheehan MT; Wermers RA; Jatoi A; Loprinzi CL; Onitilo AA
Med Hypotheses; 2020 Oct; 143():110149. PubMed ID: 32763659
[TBL] [Abstract][Full Text] [Related]
2. Hypercalcemia of malignancy and new treatment options.
Sternlicht H; Glezerman IG
Ther Clin Risk Manag; 2015; 11():1779-88. PubMed ID: 26675713
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms and treatment of hypercalcemia of malignancy.
Clines GA
Curr Opin Endocrinol Diabetes Obes; 2011 Dec; 18(6):339-46. PubMed ID: 21897221
[TBL] [Abstract][Full Text] [Related]
4. Cinacalcet for the Treatment of Humoral Hypercalcemia of Malignancy: An Introductory Case Report with a Pathophysiologic and Therapeutic Review.
Sheehan M; Tanimu S; Tanimu Y; Engel J; Onitilo A
Case Rep Oncol; 2020; 13(1):321-329. PubMed ID: 32308599
[TBL] [Abstract][Full Text] [Related]
5. Neuroendocrine Carcinoma as a Cause of Humoral Hypercalcemia of Malignancy: A Case of a Patient With Elevated Parathyroid Hormone-Related Protein.
Christensen BR; Rendo MJ; Beeler BW; Huddleston BJ; Fenderson JL
Cureus; 2022 Mar; 14(3):e23398. PubMed ID: 35481321
[TBL] [Abstract][Full Text] [Related]
6. Cinacalcet attenuates hypercalcemia observed in mice bearing either Rice H-500 Leydig cell or C26-DCT colon tumors.
Colloton M; Shatzen E; Wiemann B; Starnes C; Scully S; Henley C; Martin D
Eur J Pharmacol; 2013 Jul; 712(1-3):8-15. PubMed ID: 23623934
[TBL] [Abstract][Full Text] [Related]
7. Hypercalcemia of Malignancy: An Update on Pathogenesis and Management.
Mirrakhimov AE
N Am J Med Sci; 2015 Nov; 7(11):483-93. PubMed ID: 26713296
[TBL] [Abstract][Full Text] [Related]
8. Hypercalcemia of malignancy treated with cinacalcet.
Asonitis N; Kassi E; Kokkinos M; Giovanopoulos I; Petychaki F; Gogas H
Endocrinol Diabetes Metab Case Rep; 2017; 2017():. PubMed ID: 29399364
[TBL] [Abstract][Full Text] [Related]
9. Cinacalcet increases renal calcium excretion in PTHrP-mediated hypercalcemia: a case report.
Faiq S; Lavelle K; Hu T; Shoback D; Ku G
BMC Endocr Disord; 2023 Jun; 23(1):133. PubMed ID: 37328745
[TBL] [Abstract][Full Text] [Related]
10. Approach to diagnosis and treatment of hypercalcemia in a patient with malignancy.
Reagan P; Pani A; Rosner MH
Am J Kidney Dis; 2014 Jan; 63(1):141-7. PubMed ID: 24021907
[TBL] [Abstract][Full Text] [Related]
11. [Bone and calcium metabolism associated with malignancy. Malignancy-associated hypercalcemia.].
Tai N; Inoue D
Clin Calcium; 2018; 28(11):1503-1508. PubMed ID: 30374007
[TBL] [Abstract][Full Text] [Related]
12. Denosumab in hypercalcemia of malignancy: a case series.
Dietzek A; Connelly K; Cotugno M; Bartel S; McDonnell AM
J Oncol Pharm Pract; 2015 Apr; 21(2):143-7. PubMed ID: 24415364
[TBL] [Abstract][Full Text] [Related]
13. Role of Parathyroid Hormone Related Peptide (PTHrP) in Hypercalcemia of Malignancy and the Development of Osteolytic Metastases.
de Vernejoul MC
J Clin Rheumatol; 1997 Apr; 3(2 Suppl):109. PubMed ID: 19078166
[TBL] [Abstract][Full Text] [Related]
14. Cancer-related hypercalcemia and potential treatments.
Almuradova E; Cicin I
Front Endocrinol (Lausanne); 2023; 14():1039490. PubMed ID: 37033238
[TBL] [Abstract][Full Text] [Related]
15. Hypercalcemia of malignancy in the palliative care patient: a treatment strategy.
Kovacs CS; MacDonald SM; Chik CL; Bruera E
J Pain Symptom Manage; 1995 Apr; 10(3):224-32. PubMed ID: 7543127
[TBL] [Abstract][Full Text] [Related]
16. [Hypercalcemia, symptoms, differential diagnostics and treatment, or importance of calcium investigation].
Adam Z; Starý K; Kubinyi J; Zajíčková K; Řehák Z; Koukalová R; Tomíška M; Doubková M; Prášek J; Pourová E; Čermáková Z; Pour L; Krejčí M; Sandecká V; Ševčíková E; Ševčíková S; Král Z; Čermák A
Vnitr Lek; 2016; 62(5):370-83. PubMed ID: 27319230
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Oral Cinacalcet in Non-PTH Nonmalignant Hypercalcemia from Excess 1,25-Dihydroxyvitamin D.
Mohan S; Sheehan M; Tebben P; Wermers R
JCEM Case Rep; 2024 Mar; 2(3):luae022. PubMed ID: 38476635
[TBL] [Abstract][Full Text] [Related]
18. Increased renal calcium reabsorption by parathyroid hormone-related protein is a causative factor in the development of humoral hypercalcemia of malignancy refractory to osteoclastic bone resorption inhibitors.
Onuma E; Azuma Y; Saito H; Tsunenari T; Watanabe T; Hirabayashi M; Sato K; Yamada-Okabe H; Ogata E
Clin Cancer Res; 2005 Jun; 11(11):4198-203. PubMed ID: 15930357
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of malignancy associated hypercalcemia].
Tai N; Inoue D
Clin Calcium; 2014 Aug; 24(8):1223-8. PubMed ID: 25065875
[TBL] [Abstract][Full Text] [Related]
20. Malignant hypercalcemia.
Basso U; Maruzzo M; Roma A; Camozzi V; Luisetto G; Lumachi F
Curr Med Chem; 2011; 18(23):3462-7. PubMed ID: 21756237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
